|Bid||8,639.00 x 200|
|Ask||8,640.00 x 34100|
|Day's Range||8,636.00 - 8,679.00|
|52 Week Range||3,820.00 - 11,850.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 9, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.50|
On June 11, Leerink raised its 12-month target price on Teva from $13 to $16 while maintaining its “underperform” rating on the stock. Leerink analyst Ami Fadia revised the target prices to better reflect the improving dynamics of the company.
Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.
Teva Pharmaceutical Industries (TEVA) is the largest generics pharma manufacturer in the world. In particular, the FDA is approving generics versions of branded drugs more rapidly to shift toward a more affordable healthcare structure. Teva is on track to achieve targeted cost reductions and revenue growth.
Alder Biopharmaceuticals gapped up Friday after rival Teva Pharmaceutical scrapped a late-stage study in chronic cluster headaches.
Teva Pharmaceutical’s (TEVA) fremanezumab is a key product awaiting FDA approval. The drug is also under Phase 2 trials for the treatment of post-traumatic headache and a Phase 3 trial for the treatment of cluster headache. The drug is expected to generate significant sales for the company in the years ahead. Teva’s specialty products pipeline is shown in the chart below.
On June 13, Teva Pharmaceutical Industries (TEVA) ended the trading day at a closing price of $24.33. TEVA stock was trading ~28.0% lower than its 52-week high of $33.80 reported on July 13, 2017. Currently, TEVA stock is trading higher than its 50-day moving average of $20.52 as well as its 200-day moving average of $19.05.
Israel's Teva Pharmaceutical Inc said on Friday it would discontinue a trial testing its drug for the treatment of chronic cluster headache, after an analysis showed that the drug was unlikely to meet the study's main goal. Cluster headaches occur in cyclical patterns, or clusters, and are among the most painful types of headaches. The drug, fremanezumab, is under review by the U.S. Food and Drug Administration for prevention of migraines in adults and the company hopes to launch the drug for the disorder as soon as mid-September.
Shares of Teva Pharmaceutical Industries Ltd. dropped 1.4% in premarket trade Friday, after the drug maker said it will discontinue the phase 3 trial of its treatment for chronic cluster headaches, after ...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced a change in the clinical development program of fremanezumab in chronic cluster headache. The ENFORCE Phase III clinical development program includes a chronic cluster headache study, an episodic cluster headache study, and a long-term safety study.
On June 13, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 8.8x, compared to the industry average PE of 12.3x. The company’s forward EV-to-EBITDA, which is a capital structure–neutral valuation measure, is 11.2x. This multiple is higher than the industry average of 10.3x.
Teva Pharmaceutical Industries (TEVA) has been in the news lately and is one of the most keenly watched stocks on Wall Street. Teva Pharmaceutical has reported positive developments with respect to its restructuring plan to restore its falling sales. On June 13, Reuters surveyed 29 analysts covering Teva.
As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a non-GAAP EPS of $0.88 on revenues of ~$2.0 billion during the first quarter. Valeant had a 5.4% decline in its year-over-year revenues during the first quarter due to a 9% decrease in operating revenues. The decrease was partially offset by the favorable impact of foreign exchange—compared to revenues of ~$2.1 billion during the first quarter of 2017.
Eagle Pharmaceuticals (EGRX), a US-based drug maker and a partner of Teva Pharmaceutical that specializes in the development of critical care drugs, won a lawsuit against the US FDA. The FDA had refused to grant orphan drug status to Teva Pharmaceutical and Eagle Pharmaceuticals’ Bendeka (bendamustine hydrochloride) for the treatment of individuals with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. The orphan drug status will grant Teva Pharmaceutical an extra seven years of patent protection and market exclusivity.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw a significant share price rise of over 20% in the past couple of months on the NYSE. With many analysts covering the large-cap stock,Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks Here are the biotech stocks that were hitting 52-week highs May 24: ArQule, Inc. (NASDAQ: ARQL ) Baxter ...
Teva (TEVA) confirms that FDA has extended the goal date of the Biologics License Application (BLA) for fremanezumab to September from mid-June.
On CNBC's "Mad Money Lightning Round" , Jim Cramer advised his viewer to hold his long position in Sirius XM Holdings Inc (NASDAQ: SIRI ). He has been recommending the stock since $4 and he is ...
Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as soon as mid-September, after an initial delay. Teva and Eli Lilly are in a race to put a second migraine drug on the market, after rival Amgen won FDA approval last week for Aimovig to prevent migraine headaches in adults. Lilly has said it expects an FDA decision on its galcanezumab drug by the third quarter.
Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as early as mid-September, after an initial delay. Teva had hoped to receive approval for the drug, ...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed that the U.S. Food and Drug Administration (FDA) has extended the goal date of the Biologics License Application (BLA) for fremanezumab, an investigational therapy for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) action date for fremanezumab is set for September 16, 2018.
First bulleted paragraph, second sentence of release dated May 15, 2018 should contain the numbers 4.9, 5.3 and 6.5 . Third bulleted paragraph, second sentence, the first number should read 4.4 , and the final number should read 5.8 . Fourth paragraph, third sentence should read ...38.0, 41.7, and 37.3...